Bifogade filer
PDF
Kurs
-3,85%
Likviditet
0,12 MSEK
Kalender
| Tid* | ||
| 2025-02-27 | 08:30 | Bokslutskommuniké 2024 |
| 2024-11-28 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-07-01 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2024-06-30 | - | Årsstämma |
| 2024-05-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2023-11-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-30 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2023-02-24 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-13 | - | Årsstämma |
| 2022-05-09 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-12-16 | - | Extra Bolagsstämma 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-04 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2021-06-03 | - | Årsstämma |
| 2021-04-23 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-05 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2020-06-04 | - | Årsstämma |
| 2020-04-21 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-12 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2019-05-22 | - | Årsstämma |
| 2019-04-26 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-23 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2018-05-22 | - | Årsstämma |
| 2018-05-08 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-22 | - | Split GABA 4:1 |
| 2018-03-07 | - | Extra Bolagsstämma 2017 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-11-13 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-22 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2017-05-19 | - | Årsstämma |
| 2017-05-19 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-14 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-07 | - | Årsstämma |
| 2016-05-24 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-04 | - | Extra Bolagsstämma 2016 |
| 2016-02-22 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2016-02-19 | - | Bokslutskommuniké 2015 |
| 2015-10-23 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-21 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-17 | - | X-dag ordinarie utdelning GABA 0.00 SEK |
| 2015-02-13 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Gabather approaching a significant milestone in the clinical development of GT-002. The Company has completed 3 clinical trials so far, each showing that GT-002 is safe and well tolerated in man. The next step in the development of GT-002 is clinical studies in patients with diagnoses where effective treatments are lacking.
Discussions with specialist doctors and researchers at the Karolinska Institutet have been initiated for the design of a study in individuals with genetic predispositions to develop FTD. Currently, there are no available specific treatments for FTD, and there is still no evidence of an effective symptomatic treatment.
The goal is to create ground-breaking symptomatic treatment of FTD. The intended study is a pilot study with the aim of laying the foundation for a larger multi-centre study with GT-002. At the same time, Gabather is working towards orphan drug status "Orphan Drug Designation" (ODD) for GT-002, with a planned advisory meeting with the European Medicines Agency (EMA) during the first quarter of 2024. ODD enables a faster review and approval of the drug candidate, which also creates new opportunities for licensing deals.
"We look forward with excitement to the continued clinical development of GT-002 with good opportunities to interest a major pharmaceutical company in the further development of GT-002 as an orphan drug for the treatment of FTD. Discussions with potential licensees will intensify in 2024 with presentations of our exciting new data generated during the target-engagement study, as well as the outcome of the consultative meeting with the EMA", says Michael-Robin Witt, CEO, Gabather.
Contact Information
Michael-Robin Witt, CEO
Phone: 073-687 28 39
E-mail: mrw@gabather.com
About Gabather
Gabather is a clinical-stage pharmaceutical company aiming to transform the treatment of neuropsychiatric disorders. The Company was founded as a response to the significant unmet need and lack of innovative therapeutics in the mental health treatment landscape. Gabather is dedicated to developing innovative therapeutics for the treatment of a broad range of neuropsychiatric disorders. The goal is to accelerate the development of new groundbreaking medicines to achieve clinically meaningful therapies for the patients.
For more information, please visit: www.gabather.com
Certified Adviser
Corpura Fondkommission AB
Phone: +4672-252 34 51
Email: ca@corpura.se
www.corpura.se